Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | -91.67% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.23 | N/A | -91.67% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management's tone was defensive, highlighting ongoing challenges. They did not offer specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.
Biocryst Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a significant drop in stock price by 13.08%. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance and profitability. Overall, the results indicate ongoing challenges for the company.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UNUM GROUP
Aug 5, 2013